|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–49. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Browne P, Chandraratna D, Angood C,
Tremlett H, Baker C, Taylor BV and Thompson AJ: Atlas of multiple
sclerosis 2013: A growing global problem with widespread inequity.
Neurology. 83:1022–1024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghajarzadeh M, Jalilian R, Eskandari G,
Ali Sahraian M and Reza Azimi A: Validity and reliability of
persian version of modified fatigue impact scale (MFIS)
questionnaire in Iranian patients with multiple sclerosis. Disabil
Rehabil. 35:1509–1512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lalmohamed A, Bazelier MT, Van Staa TP,
Uitdehaag BM, Leufkens HG, De Boer A and De Vries F: Causes of
death in patients with multiple sclerosis and matched referent
subjects: A population-based cohort study. Eur J Neurol.
19:1007–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yasunaga M: Antibody therapeutics and
immunoregulation in cancer and autoimmune disease. Semin Cancer
Biol. 64:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Z, Liu H, Yang Y, Zhou J, Zhao L,
Chen H, Fei Y, Zhang W, Li M, Zhao Y, et al: The five major
autoimmune diseases increase the risk of cancer: Epidemiological
data from a large-scale cohort study in China. Cancer Commun
(Lond). 42:435–446. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jick SS, Li L, Falcone GJ, Vassilev ZP and
Wallander MA: Mortality of patients with multiple sclerosis: A
cohort study in UK primary care. J Neurol. 261:1508–1517. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moisset X, Perié M, Pereira B, Dumont E,
Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F and Clavelou P:
Decreased prevalence of cancer in patients with multiple sclerosis:
A case-control study. PLoS One. 12:e01881202017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bosco-Lévy P, Foch C, Grelaud A, Sabidó M,
Lacueille C, Jové J, Boutmy E and Blin P: Incidence and risk of
cancer among multiple sclerosis patients: A matched
population-based cohort study. Eur J Neurol. 29:1091–1099. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kingwell E, Bajdik C, Phillips N, Zhu F,
Oger J, Hashimoto S and Tremlett H: Cancer risk in multiple
sclerosis: Findings from British Columbia, Canada. Brain.
135:2973–2979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marrie RA, Maxwell C, Mahar A, Ekuma O,
McClintock C, Seitz D, Webber C and Groome PA: Cancer incidence and
mortality rates in multiple sclerosis: A matched cohort study.
Neurology. 96:e501–e512. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. Rev Esp Cardiol (Engl Ed).
74:790–799. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. 2014.Available from:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
|
|
15
|
Nielsen NM, Rostgaard K, Rasmussen S,
Koch-Henriksen N, Storm HH, Melbye M and Hjalgrim H: Cancer risk
among patients with multiple sclerosis: A population-based register
study. Int J Cancer. 118:979–984. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bahmanyar S, Montgomery SM, Hillert J,
Ekbom A and Olsson T: Cancer risk among patients with multiple
sclerosis and their parents. Neurology. 72:1170–1177. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu X, Ji J, Forsti A, Sundquist K,
Sundquist J and Hemminki K: Autoimmune disease and subsequent
urological cancer. J Urol. 189:2262–2268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grytten N, Myhr KM, Celius EG, Benjaminsen
E, Kampman M, Midgard R, Vatne A, Aarseth JH, Riise T and
Torkildsen Ø: Risk of cancer among multiple sclerosis patients,
siblings, and population controls: A prospective cohort study. Mult
Scler. 26:1569–1580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hongell K, Kurki S, Sumelahti ML and
Soilu-Hänninen M: Risk of cancer among Finnish multiple sclerosis
patients. Mult Scler Relat Disord. 35:221–227. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marrie RA, Reider N, Cohen J, Stuve O,
Trojano M, Sorensen PS, Reingold SC and Cutter G: A systematic
review of the incidence and prevalence of cancer in multiple
sclerosis. Mult Scler. 21:294–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kyritsis AP, Boussios S and Pavlidis N:
Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol
Hematol. 98:29–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ngu JH, Gearry RB, Frampton CM and Stedman
CA: Mortality and the risk of malignancy in autoimmune liver
diseases: A population-based study in Canterbury, New Zealand.
Hepatology. 55:522–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shariati M, Shaygannejad V, Abbasirad F,
Hosseininasab F, Kazemi M, Mirmosayyeb O and Esmaeil N: Silymarin
restores regulatory T cells (Tregs) function in multiple sclerosis
(MS) patients in vitro. Inflammation. 42:1203–1214. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oleinika K, Nibbs RJ, Graham GJ and Fraser
AR: Suppression, subversion and escape: The role of regulatory T
cells in cancer progression. Clin Exp Immunol. 171:36–45. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ysrraelit MC and Correale J: Impact of
andropause on multiple sclerosis. Front Neurol. 12:7663082021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Collongues N, Patte-Mensah C, De Seze J,
Mensah-Nyagan AG and Derfuss T: Testosterone and estrogen in
multiple sclerosis: From pathophysiology to therapeutics. Expert
Rev Neurother. 18:515–522. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Watts EL, Perez-Cornago A, Fensom GK,
Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM,
Tsilidis KK, et al: Circulating free testosterone and risk of
aggressive prostate cancer: Prospective and Mendelian randomisation
analyses in international consortia. Int J Cancer. 151:1033–1046.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Watts EL, Appleby PN, Perez-Cornago A,
Bueno-de-Mesquita HB, Chan JM, Chen C, Cohn BA, Cook MB, Flicker L,
Freedman ND, et al: Low free testosterone and prostate cancer risk:
A collaborative analysis of 20 prospective studies. Eur Urol.
74:585–594. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thormann A, Koch-Henriksen N, Laursen B,
Sørensen PS and Magyari M: Inverse comorbidity in multiple
sclerosis: Findings in a complete nationwide cohort. Mult Scler
Relat Disord. 10:181–186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Godtman RA, Kollberg KS, Pihl CG, Månsson
M and Hugosson J: The association between age, prostate cancer
risk, and higher gleason score in a long-term screening program:
Results from the Göteborg-1 Prostate cancer screening trial. Eur
Urol. 82:311–317. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loeb S, Fu BC, Bauer SR, Pernar CH, Chan
JM, Van Blarigan EL, Giovannucci EL, Kenfield SA and Mucci LA:
Association of plant-based diet index with prostate cancer risk. Am
J Clin Nutr. 115:662–670. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghajarzadeh M, Mohammadi A and Sahraian
MA: Risk of cancer in multiple sclerosis (MS): A systematic review
and meta-analysis. Autoimmun Rev. 19:1026502020. View Article : Google Scholar : PubMed/NCBI
|
